Wednesday, December 31, 2025
Novo wins favorable Supreme Court ruling in China related to key Wegovy patent
Novo Nordisk has won a favorable Supreme People's Court ruling in China that upholds the validity of the semaglutide compound patent, the key active ingredient in its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.